Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Pradaxa (dabigatran etexilate) – Oral Direct Thrombin Inhibitor

Venous thromboembolism is the third most common cardiovascular disease after heart attack and stroke.

  • human heart
  • Venous thromboembolism
  • Risk of developing DVT or PE
  • Oral anticoagulants
  • Pradaxa (dabigatran etexilate)

Go Top